Jupiter Life Line Hospitals Ltd Q4 FY2024 Concall Summary

Key Takeaways

• Steady quarter, expansion-led story: Revenue grew ~18% YoY with ARPOB improvement from insurance renegotiations and a self-payer price hike, while Q4 saw seasonal cost bumps from gratuity and marketing.
• Two new hospitals greenlit: A 500-bed South Pune hospital on a 10-year flat lease with a buy option, and 75 additional beds in Indore, together adding visibility toward the 2,500-bed target.
• Indore is scaling fast: Occupancy nearing 60% triggered the capacity expansion; the hospital is still maturing its specialty mix, which should lift ARPOB further over the next year or two.
• Dombivli on track, losses sized: Construction slated for Q4 FY26 completion; management expects a ~₹2 cr monthly EBITDA loss at low occupancy, with break-even around year two.
• What to watch next quarter: Progress on regulatory approvals for the new Pune hospital, Indore's occupancy trajectory as new beds come online, and any further land acquisition for the next greenfield.

Expansion Pipeline & Bed Target

• Short-term bed target: Management aims to reach 2,500 beds; with Dombivli and the new Pune hospital, visibility extends from ~1,200 to ~2,200 beds, leaving one more hospital to secure.
• Next hospital land: The company hopes to secure one more land parcel this year in Western India, deploying cash generated from operations.
• Dombivli construction: Progressing as expected, slated for completion by Q4 FY26.
• Indore capacity expansion: Permission secured to build two additional floors, adding ~75 beds and taking total capacity north of 300 beds; these should be ready by end of this year and operational next year.
• Indore further expansion trigger: When occupancy on the 75 new beds reaches 60%-65%, management will plan the next phase.
• Pune suite rooms: 22 new suite rooms to be commissioned to enhance operational capacity at the existing Baner hospital.

Dr. Ankit Thakker: "We have a definitive right to buy this land anytime after three years in our lease document... we have a flat lease which will not escalate for 10 years. And at any point after three years, we have a definitive right to buy."

New Pune Hospital

• Location and scale: Second Pune hospital in South Pune (Ganga Dham area, Bibwewadi), ~1 hour drive from the current Baner hospital; 500 beds on ~3 acres.
• Lease structure: 10-year flat, non-escalating lease with a definitive right to buy the land anytime after three years.
• Micro-market logic: Pune's population of 0.6-0.7 crore faces worsening cross-city travel times, creating demand for healthcare solutions in multiple micro-markets, analogous to Mumbai's Eastern vs Western Suburbs dynamic.
• CAPEX and timeline: Total project cost estimated at ₹200-250 cr; no heavy CAPEX expected in the current financial year as the first 3-4 months involve excavation and site mobilization with low spend.
• Regulatory approvals pending: Management will announce the construction commencement date once environmental clearances and municipal approvals are obtained; the operations start date will follow that announcement.

Unit-Level Performance

Indore

• Occupancy and capacity: Nearing 60% of installed capacity, which prompted the 75-bed expansion; insurance empanelments are all complete.
• ARPOB drivers: Specialty mix still has room to mature, with recent additions including complex cancer work, skin cancer radiation, and a single-patient liver and kidney transplant; ARPOB improvement expected within the next year or two.
• Margin impact from expansion: The first 3-6 months of the new facility may see higher fixed costs and under-utilization, causing a small margin impact for one or two quarters, after which margins should stabilize and improve on operating leverage.

Pune (Baner)

• Occupancy headroom: Can grow from 62% to mid-70% occupancy, adding roughly 10 percentage points.
• ARPOB outlook: ARPOB is at a good level and should see inflation-linked growth going forward; it is not a function of occupancy.
• Expansion impact: The new suite rooms and the South Pune project are not large enough individually to significantly impact margins at the existing hospital.

Thane

• Mature asset: Serves as the benchmark for Dombivli's trajectory; management expects Dombivli to be nearer to Thane's performance within three years.

Revenue Drivers & Pricing

• Insurance renegotiations: Contracts renegotiated with insurance companies in Thane and Pune in Q3, securing a high single-digit (8%-10%) price hike.
• Self-payer price hike: Around 5% price rise taken for self-payers in February/March, partially contributing to the ARPOB improvement; such hikes could happen on an annual basis depending on local market conditions.
• Case mix as ARPOB lever: Case mix optimization drives ARPOB in the first 3-5 years of a new hospital as departments get established and doctors join; after 5 years, most services are on offer and levers to drive case mix are limited.
• ALOS philosophy: Management explicitly disagrees that reducing ALOS improves financial performance or efficiencies, stating that ALOS is a function of treatment mix and cannot be compared hospital-to-hospital.

Dr. Ankit Thakker: "We don't want to tell our patient that if you need a low-cost dialysis then you manage your problems. But if you need a transplant come to me or if traditionally people said Pediatrics was low margin kind of work, if your child is in trouble, go somewhere else but if you are in trouble, I will take care of you."

Costs & Margins

• Q4 seasonal employee costs: Q4 employee benefits include gratuity and leave encashment provisions from actuarial valuations done at year-end, so the full-year impact hits Q4; this pattern could continue next year.
• Q4 seasonal other costs: Q4 includes annual provisions and write-offs (~0.3% of annual revenue) and a large marathon event to promote awareness of children's congenital heart diseases.
• Dombivli ramp-up losses: Management expects an EBITDA loss of ~₹2 crores per month (~₹25 crores annually) at 20%-30% occupancy; break-even is projected at 40%-45% occupancy, around 2 years.
• Dombivli trajectory: Could follow Thane's path (break-even in first year) or more conservatively Pune/Indore's path (break-even in second year); within three years, performance should be nearer to Thane.

Dr. Ankit Thakker: "I'm sorry, but I disagree with that analysis. The conclusion is that reducing ALOS may not improve your financial performance or efficiencies because the inputs are different, but that might be a longish discussion. I don't know if this is the right platform for that."

Guidance & Commitments

Key Metrics